Follow-up of Bronchial Precancerous Lesions and  Carcinoma <i>in Situ</i> Using Fluorescence Endoscopy

Bota, S.; Auliac, J.B.; Paris, Christophe; Metayer, J; Sesboüé, Richard; Nouvet, G; Thiberville, Luc

doi:10.1164/ajrccm.164.9.2012147

Cited by 192 publications

(165 citation statements)

References 25 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…S1). These findings are consistent with medical observations that very few lesions ever progress to cancer (26,27). Like our model, these studies also find that most lesions regress to undetectable size.…”

Section: Significancesupporting

confidence: 91%

Tug-of-war between driver and passenger mutations in cancer and other adaptive processes

McFarland

Mirny

Korolev

2014

Proc. Natl. Acad. Sci. U.S.A.

149

187

View full text Add to dashboard Cite

Cancer progression is an example of a rapid adaptive process where evolving new traits is essential for survival and requires a high mutation rate. Precancerous cells acquire a few key mutations that drive rapid population growth and carcinogenesis. Cancer genomics demonstrates that these few driver mutations occur alongside thousands of random passenger mutations-a natural consequence of cancer's elevated mutation rate. Some passengers are deleterious to cancer cells, yet have been largely ignored in cancer research. In population genetics, however, the accumulation of mildly deleterious mutations has been shown to cause population meltdown. Here we develop a stochastic population model where beneficial drivers engage in a tug-of-war with frequent mildly deleterious passengers. These passengers present a barrier to cancer progression describable by a critical population size, below which most lesions fail to progress, and a critical mutation rate, above which cancers melt down. We find support for this model in cancer age-incidence and cancer genomics data that also allow us to estimate the fitness advantage of drivers and fitness costs of passengers. We identify two regimes of adaptive evolutionary dynamics and use these regimes to understand successes and failures of different treatment strategies. A tumor's load of deleterious passengers can explain previously paradoxical treatment outcomes and suggest that it could potentially serve as a biomarker of response to mutagenic therapies. The collective deleterious effect of passengers is currently an unexploited therapeutic target. We discuss how their effects might be exacerbated by current and future therapies.

show abstract

Section: Significancesupporting

confidence: 91%

Tug-of-war between driver and passenger mutations in cancer and other adaptive processes

McFarland

Mirny

Korolev

2014

Proc. Natl. Acad. Sci. U.S.A.

149

187

View full text Add to dashboard Cite

show abstract

“…Prospective studies have now shown that, although the majority of high-grade dysplastic and in situ carcinomatous lesions of the bronchus may progress, there is are some (the exact percentage remains to be clarified) that do not progress, and some may even regress. 13,14 Thus, carcinoma in situ of the bronchus may not be entirely analogous to the more common invasive lung carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Pathologic review of the Mayo Lung Project

Colby

Tazelaar

Travis

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDIn the Mayo Lung Project Screening Trial, there were more carcinomas identified in the screened group compared with the control group. The screened group had better survival, but there was no difference in lung carcinoma mortality between the screened group and the control group. The purpose of this study was to review all available original pathology from the trial to determine whether overdiagnosis (carcinomas that do not result in the death of the patient) or misdiagnosis of lung carcinoma may explain this discrepancy.METHODSAll available lung pathology slides from patients who underwent surgery at the Mayo Clinic were reviewed independently by three blinded lung pathologists. Tumors were classified according to the 1999 World Health Organization criteria. In addition, agreement among the pathologists was assessed.RESULTSAmong 106 patients who underwent surgery at the Mayo Clinic, slides were available for review from 105 patients, including 77 slides from the screened group and 28 slides from the control group. The original diagnosis of carcinoma was confirmed in all patients. In 7 patients (6.7%), there was unanimous agreement that the lesion was preinvasive (carcinoma in situ), and these lesions all were from the screened group. In 90 patients (85.5%), there was unanimous agreement that the tumors were invasive. In 8 patients (7.8%), there was some disagreement between the observers about whether lesions were invasive or preinvasive; 7 of these 8 lesions were from the screened group. The level of agreement among pathologists for invasive carcinomas was > 94% for all comparisons, and the κ statistic ranged from 0.67 (substantial agreement) to 0.84 (almost perfect agreement). There was good agreement among the pathologists about tumor cell type with the κ statistic ≥ 0.65.CONCLUSIONSThe histologic diagnosis of carcinoma was confirmed for all 105 slides that were reviewed. The results of this study indicate that misdiagnosis does not explain the increased numbers of carcinomas identified in the screened group. The increased numbers of in situ carcinomas in the screened group resulted in increased numbers of squamous carcinomas in the screened group compared with the control group and may have contributed to the better survival. It is possible that carcinoma in situ accounted for some instances of overdiagnosis. Cancer 2002;95:2361–5. © 2002 American Cancer Society.DOI 10.1002/cncr.10930

show abstract

“…In particular, early squamous cell carcinomas in the large central airways escape CT detection, as do premalignant lesions like severe dysplasia and carcinoma-in-situ (CIS). These precursor lesions have been shown to progress to invasive squamous cell carcinoma in over 50% of cases in some studies (55). Indeed, absent severe dysplasia, the progression of low-grade dysplasia to CIS and invasive squamous cell carcinoma is not negligible, suggesting that each of these preneoplastic lesions must be independently considered to have malignant clones (56).…”

Section: Beyond Ct Screening-molecular Biomarkersmentioning

confidence: 99%

Lung Cancer Screening with CT

Aberle

Brown

2008

Clinics in Chest Medicine

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death in the United States. In 2007, it is estimated that 160,390 lung cancer deaths will occur in the US, representing 29% of all cancer deaths (1). Roughly 87% of lung cancers are attributed to cigarette smoking (2). Although cancer risk is attenuated by smoking cessation, the risk is not eliminated, and lung cancer now occurs with equal frequency in current and former smokers (3). Moreover, other factors clearly influence risk, including age; family history; chronic obstructive pulmonary disease; pulmonary fibrosis; and exposures to environmental radon, asbestos, and certain other occupational agents (4). Realistically, lung cancer will likely remain at epidemic proportions for decades to come.Non-small cell lung cancer (NSCLC), which accounts for 75-80% of all lung cancers, is typically diagnosed when disease is locally advanced or there are systemic metastases (5), explaining the dismal overall five-year survival of 15% (6). In contrast, the five-year survival of individuals with surgically resected, early stage NSCLC approaches 75% (6,7). These differences have fueled the impetus to find a screening test that can detect NSCLC in its early preclinical stages, when surgical resection is most likely to prolong life and potentially reduce lung cancer mortality. Although earlier randomized controlled trials of lung cancer screening using chest radiography and sputum cytology failed to show reduced lung cancer mortality, computed tomography (CT) is a much more sensitive test for detecting small lung nodules, and has generated considerable enthusiasm as a potential contemporary screening tool for lung cancer.

show abstract

Follow-up of Bronchial Precancerous Lesions and Carcinoma in Situ Using Fluorescence Endoscopy

Cited by 192 publications

References 25 publications

Tug-of-war between driver and passenger mutations in cancer and other adaptive processes

Tug-of-war between driver and passenger mutations in cancer and other adaptive processes

Pathologic review of the Mayo Lung Project

Lung Cancer Screening with CT

Contact Info

Product

Resources

About